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Pregnancies in women with epilepsy are high risk and need careful management by both the medical and obstetric teams due to
the increased incidence of complications and adverse outcomes of pregnancy.
By the time a pregnant woman with epilepsy presents, the foetus is virtually fully formed and the opportunity for altering
drug treatment has passed. Women need to be counselled and told to seek advice about their anticonvulsant therapy should they
wish to become pregnant. All major anticonvulsant drugs are teratogenic but the main risk to the developing foetus appears to
be when the mother is on polytherapy especially if sodium valproate forms part of the combination. Folate supplements (5 mg)
before conception are advisable.
There appears to be a minor but significant increased risk of maternal complications in women with epilepsy such as
hyperemesis gravidarum, pre-eclampsia and eclampsia, vaginal bleeding and premature labour. In the majority of women seizure
control will not alter during pregnancy. Oral vitamin K should be given to the mother receiving enzyme-inducing antiepileptic
drugs.
Post-natal infant development: there is an increased risk of prematurity (9–11%), stillbirth, neonatal and perinatal death,
haemorrhagic disease of the newborn, low Apgar scores and low birth weight (7–10%).
Breast feeding: virtually all the anticonvulsant drugs are excreted in breast milk in low concentrations. Feeding difficulties,
irritability and lethargy can occur. However, the benefits of breast feeding usually far outweigh any minor risks to the baby.
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INTRODUCTION
The management of pregnant women with epilepsy is
becoming of increasing importance as the risk factors
for adverse outcome of pregnancy are becoming
more clearly delineated. The majority of women with
epilepsy will have a normal pregnancy and delivery,
an unchanged seizure frequency and over a 90%
chance of a normal baby. However, many women
still present in early pregnancy on anticonvulsant drug
combinations which significantly increase their risk of
a malformed infant.
Pregnancies in women with epilepsy are high risk
and need careful management by both the medical
and obstetric teams due to the increased incidence of
complications and adverse outcomes of pregnancy.
PRE-CONCEPTION
By the time a pregnant woman with epilepsy presents
to an obstetrician or physician, the foetus is virtually
fully formed and the opportunity for altering drug
treatment has passed. Women of child-bearing age
need to be counselled and told to seek advice about
their anticonvulsant therapy should they wish to
become pregnant. Not only does the necessity for
anticonvulsant therapy need to be reconsidered, but
the woman ought to be on the lowest possible dose
of a single anticonvulsant agent which will adequately
control seizures. All major first line anticonvulsant
drugs (carbamazepine, sodium valproate, phenytoin,
phenobarbitone and mysoline) are teratogenic but the
main risk to the developing foetus appears to be when
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the mother is on polytherapy especially if sodium
valproate forms part of the combination. Folate
supplements before conception are advisable1. The
Department of Health has suggested that women with
epilepsy should receive high dose folate supplements
(5 mg)2.
A study from Birmingham demonstrated the ben-
efits of pre-conception counselling and folic acid
supplements. None of the women (85) who received
counselling had a foetal abnormality detected during
pregnancy or after delivery, compared to 11 out of
59 women who presented themselves to the clinic in
a pregnant state. No patient in either group who took
folic acid pre-conception had a foetal abnormality
compared to 23% of women not taking folic acid2a.
PREGNANCY
Pharmacokinetics of antiepileptic drugs in
pregnant women
In the majority of women seizure control will
not alter during pregnancy. A third will have an
increase in seizure frequency, but in many, this
due to deliberate non-compliance because of worries
over the adverse effects of anticonvulsants on the
developing foetus. An increase in seizures seems to
be unrelated to the type or duration of epilepsy or
seizure frequency in previous pregnancies but tends
to occur in women who have low anticonvulsant
levels at the beginning of pregnancy3. The reason
for this increased risk are not fully understood but
include deliberate non-compliance, sleep deprivation,
alterations in antiepileptic drug kinetics, weight gain,
metabolic changes and decreased albumin levels.
At constant drug dosage, the serum levels of most
antiepileptic drugs tend to decrease during pregnancy,
but return to pre-pregnancy levels within a month of
delivery4.
The changes in antiepileptic drug concentrations
usually began within 10 weeks of pregnancy and
returned to baseline values within a month of delivery
in two thirds of the women receiving phenytoin. The
return to pre-pregnancy levels appear to be slower for
carbamazapine and phenobarbitone5.
Recent studies suggest that measuring total
antiepileptic drug levels during pregnancy may
be misleading, and monitoring of unbound levels
should be taken instead if drug level monitoring is
undertaken2, 6. Practically it is sensible to increase
the antiepileptic drug dosage if seizure frequency
increases. It also has to be appreciated that many of
the women may be deliberately non-compliant with
therapy during pregnancy. There is also the problem of
women who are seizure-free and driving, who would
lose her driving license after a single seizure. In the
majority of women the increase in seizure frequency is
in the first trimester7. However, this does not correlate
with changes in anticonvulsant concentrations which
differ for each drug6.
Effects of maternal seizures on the foetus
Profound alterations in the acid–base equilibrium
occur immediately after a generalized tonic–clonic
seizure. These metabolic changes are probably trans-
ferred to the foetus, as there are alterations in the
foetal heart rate compatible with foetal acidosis8, 9.
Prospective studies do not suggest that there is an
association between maternal tonic–clonic seizures
during pregnancy and malformations10, 11. However,
organogenesis is a very short period of time and only
a few patients experience seizures during this time.
There are a few isolated reports indicating severe
hypoxia in a mother can be teratogenic12. It appears
therefore that a healthy foetus is remarkably resistant
to problems secondary to maternal seizures. There
are anecdotal reports of intrauterine deaths in after
a seizure13, however, than these do appear to be
rare. In a study of a 152 tonic–clonic seizures during
pregnancy in 154 women, there were no immediate
foetal deaths or obstetric complications14.
Seizures during labour
A tonic–clonic seizure occurs during labour in 1–
2% of women with epilepsy and within 24 hours of
delivery in another 1–2%, which represents a risk
of greater than nine times the average probability
of a seizure during the rest of pregnancy14. A
generalized tonic–clonic seizure during labour can
cause a transient foetal bradycardia, reduced beat-to-
beat variability, and decelerations for about 30 minutes
after a seizure15, 16. However, a case report suggests
that foetal bradycardia during maternal seizures does
not develop unless the mother develops acidosis17.
Vitamin K supplements
It has been suggested that oral vitamin K should
be given to the mother receiving enzyme-inducing
antiepileptic drugs (phenytoin, carbamazepine, oxcar-
bazepine, topiramate or phenobarbitone) in the last
month of pregnancy to protect the foetus against
haemorrhagic disease of the newborn1. In these babies
it tends to occur within 24 hours of birth and the
protection given by only giving vitamin K to the baby
after delivery may not be adequate.
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Pre-term delivery
Women taking enzyme-inducing antiepileptic drugs
who require antenatal steroid therapy because of a
perceived risk of pre-term delivery should receive a
steroid regime providing a total of 48 mg beclometha-
sone (rather than 24 mg advocated for other women).
This is because steroid metabolism is induced by
enzyme-inducing antiepileptic drugs. Oral vitamin K
therapy (20 mg daily) should also be started.
FOETAL DEVELOPMENT
Infants born to women receiving anticonvulsant drugs
have at least double the risk of being born with
an anomaly or a malformation1. If the mother with
epilepsy is on no treatment, there is a small increase
in the risk of abnormalities such as a cleft palate or
spina bifida. Paternal epilepsy does not influence this.
After allowing for this the most likely aetiological
factor to account for the increase in malformations
appears to be anticonvulsant therapy19. The four
major anticonvulsant drugs (barbiturates, phenytoin,
carbamazepine and sodium valproate) are all terato-
genic in animal studies. The abnormalities reported
are similar to those seen in humans. The majority
of the malformations are minor and form part of
what appears to be a foetal anticonvulsant syndrome1,
the incidence of which varies between 1.25% and
11.5% in exposed infants compared to 2.3% in the
general population1, 20–22. Features described include
hypertelorism, an abnormal midface, epicanthic folds,
microcephaly, transverse palmar creases and minor
skeletal abnormalities. More serious malformations
include spina bifida and congenital heart disease
which can be screened for in utero by ultrasound1.
Studies from Japan have clearly demonstrated that
the risk of an abnormal foetus is related to the
number and dosage of the anticonvulsant drugs19. A
prospective study showed that the risk of a malformed
infant could be decreased from 13.5 to 6.2% by
ensuring that more women received monotherapy in
the lowest possible dose19.
The organs in the body are sensitive to exogenous
agents that cause or are suspected of causing
teratogenic effects at different dates. For example, a
cleft palate cannot be caused by drugs administered
60 days after conception, since by this date the palate
is closed23.
Days 21 to 56 represent the period when the
foetus is considered to be most sensitive to the
induction of malformations by exogenous agents,
either in single organs or syndromes of malformations.
This is also the period of extensive cell migration,
morphogenetic movements, cell-to-cell and cell-to-
matrix interactions etc. Known human teratogens
which are active during this period, include sodium
valproate and ethanol. After the eighth week, exposure
to teratogens is not considered to result in any major
morphological malformations. However, development
is a continuum, in the foetal as well as the embryonic
period. Moreover, any particular drug may affect
processes in the embryonic as well as the foetal
period23.
Major malformation patterns associated with
antiepileptic drugs
Phenytoin
Hydantoins in monotherapy have been associated with
a pattern of malformations called the foetal hydantoin
syndrome24. This consists of pre-natal and post-natal
growth deficiency, microcephaly and developmental
delay, in combination with dysmorphic craniofacial
abnormalities and nail and distal pharyngeal hypopla-
sia. Unexpected major congenital malformations more
often associated with phenytoin are facial clefts and
congenital heart defects25–27.There appears to be no
consistent dose–response relationship for phenytoin
and major or minor malformations, neither is there a
relationship with maternal antiepileptic drug plasma
levels28, 29.
Barbiturates
Barbiturates in monotherapy have also been associated
with congenital heart defects and facial clefts25–27.
There also appears to be a specific pattern of minor
anomalies and dysmorphic features such as growth
deficiency and craniofacial and/or limb abnormali-
ties30, 31. Again no clear dose–response relationship or
relationship to plasma levels has been found.
Carbamazapine
Recent studies have suggested there is an association
between carbamazapine and congenital malformations
in about the same frequency as for barbiturates
and phenytoin but the patterns of malformation are
different. Initial studies suggested that carbamazapine
therapy was associated with abnormal growth param-
eters such as reduced head circumference, weight
and length at birth32, 33. Later studies have reported
associations with hip dislocation, inguinal hernia,
hypospadias, congenital heart defects and neural tube
defects (0.5 to 1%)29, 34, 35.
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Sodium valproate
Sodium valproate appears to be the only antiepileptic
drug for which a dose–response relationship has been
observed. A high daily dose above 1000 mg/day
or a high peak dose appears to increase the risk
of major congenital malformations29. Malformations
associated with sodium valproate include neural tube
defects (2.5%), craniofacial, skeletal, cardiovascular,
urogenital and cerebral defects36–39. A relationship
between valproate and radial ray aplasia, rib and
vertebral anomalies has also been reported40, 41. Data
from the UK pregnancy register has shown that
sodium valproate is significantly more teratogenic
than carbamazepine and therefore sodium valproate
should be avoided in pregnancy41a.
Ethosuximide
Major congenital malformations, such as facial clefts,
have been associated with ethosuximide, but mainly in
combination therapies such as barbiturates42.
Benzodiazepines
Initial reports suggested an association between orofa-
cial clefts and benzodiazepines but later studies have
not been able to confirm these findings42. However,
it has been suggested that the combination of sodium
valproate and benzodiazepines may lead to more
pronounced dysmorphism compared to children pre-
natally exposed to sodium valproate monotherapy43.
This may be due to an amplifying action on
benzodiazepines on valproate teratogenicity42, 44.
Secondary prevention of major foetal
malformations
Ultrasound screening for major malformation can be
performed in between 18 and 20 weeks of pregnancy.
It may provide the mother the option of terminating
the pregnancy. However, not all malformations can be
detected pre-natally, and even when detected, it may
not be possible to give the prognosis. Other methods
include serum alpha foetoprotein and amniocentesis in
order to measure the alpha 1 foetoprotein.
Minor congenital malformations
Genetic traits associated with epilepsy may contribute
to malformations, development defects or dysfunction
independent of drug exposure45, 46.
Eight prospective studies have looked at minor
physical anomalies in children born to mothers
with epilepsy. All studies show an increase in
minor anomalies in children whose mothers have
epilepsy compared to control children. An excess of
dysmorphic features, especially epicanthus, was noted
not only in the children but also in the mothers with
epilepsy47, 48. There does appear to be a slight increase
in the risk of cognitive impairment among children
born to mothers with epilepsy compared to those with
non-epileptic parents48. A recent retrospective study
has shown that children born to mothers receiving
sodium valproate during pregnancy are more likely to
need additional help at school48a.
Which antiepileptic drug during pregnancy?
An important question is which anticonvulsant drug
carries the lowest risk during pregnancy. A recent
overview suggests that of the older first-line therapies,
carbamazepine therapy carries slightly less risk
compared to valproate, phenytoin, phenobarbitone or
mysoline22. However, it is probably best if seizure
control is good, to leave the treatment unchanged
provided a single anticonvulsant is used in the lowest
possible dose. Worries have been expressed about
the incidence (1–2%) of spina bifida associated with
sodium valproate29, particularly as sodium valproate is
treatment of choice for primary generalized epilepsies.
However, spina bifida is an abnormality which can
be screened for in early pregnancy and a more recent
study has suggested there is a 0.5–1% risk of spina
bifida associated with carbamazepine49. The risk of
sodium valproate teratogenicity may be decreased by
keeping the total dose below 1000 mg and using
Epilim chrono as the peak dose of sodium valproate is
important with regards to teratogenicity2, 29. However,
as data from the UK pregnancy register has shown
that sodium valproate is significantly more terato-
genic than carbamazepine41a and another study has
highlighted educational problems in children exposed
to sodium valproate during pregnancy48a, sodium
valproate should be avoided during pregnancy.
A literature review suggests that drug combinations
especially those including sodium valproate, should
also be avoided. There seems to be an increased risk of
foetal malformation, possibly related to the inhibition
of metabolism of anticonvulsants, leading in particular
to intermediary metabolites, which may play a role in
teratogenicity1.
The two newer second-line anticonvulsant therapies
(gabapentin and lamotrigine) do not appear to be
teratogenic in animal studies. Pregnancies in women
taking these drugs are few, but it is likely in the
future that these will be the drugs of choice for
women of childbearing age. Topiramate, one of
the most recent anticonvulsants to be licensed, is
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teratogenic in animal studies—it causes limb and
digit reduction. Tiagabine and levatiracetam, the
most recently licensed antiepileptic drugs do not
appear to be teratogenic in animal studies but human
pregnancies are few2.
Maternal complications of epilepsy and
pregnancy
There appears to be a minor but significantly increased
risk of maternal complications in women with epilepsy
such as hyperemesis gravidarum, pre-eclampsia and
eclampsia, vaginal bleeding and premature labour.
The majority of reports suggest that spontaneous
abortions are no more common in women with
epilepsy compared to the general population50, 51.
Some studies have suggested pre-eclampsia is more
frequent in women with epilepsy compared with
controls and tends to be more severe52–54. Induction
of labour is used more frequently in women with
epilepsy, and was over four times more common
in women with epilepsy compared with controls
in one study53. Another study showed that there
was an increased incidence of instrumental delivery
in women with epilepsy, with caesarean sections
and forceps or vacuum extraction being more than
twice as frequent as in controls55. Some studies
have suggested that the amount of blood lost during
delivery is higher amongst women with epilepsy.
Ablatio placentae, vitamin K deficiency and hypotonic
uterine activity have been suggested as important
causes of vaginal bleeding52, 54. Other more recent
studies have failed to confirm these findings and it
may be that maternal coagulation deficiencies have
been prevented by the use of prophylactic vitamin K
supplements15, 50, 56. Neither pre-term nor prolonged
labour seemed to occur more frequently in women
with epilepsy compared with controls15, 50, 56.
POST-NATAL INFANT DEVELOPMENT
When a woman with epilepsy is pregnant the greater
the risk of an adverse outcome of pregnancy extends
to the child too. There is an increased risk of
prematurity (9–11%), stillbirth, neonatal and perinatal
death, haemorrhagic disease of the newborn, low
Apgar scores and low birth weight (7–10%)1.
Low birth weight for gestational age is more
frequent in infants of women with epilepsy than in
controls52, 57. There also appears to be an increased
incidence of intrauterine growth retardation amongst
infants of women with untreated epilepsy56, 58, 59. A
slight, but significantly smaller head circumference
has been reported amongst infants born to mothers
with epilepsy but neonatal birth length appears to
be unaffected11, 58, 60. Placenta weight, placental mor-
phology and growth factor receptors are unaffected
by antiepileptic drug exposure61, 62. Low Apgar scores
and the development of asphyxia has been found in a
larger proportion of infants of women with epilepsy
than in controls57. In a study of sodium valproate
monotherapy, almost half the babies developed foetal
distress during labour compared to 9% of controls,
and 28% had low Apgar scores compared with 5.5%
amongst controls40. Transient foetal distress can be
caused by a maternal tonic–clonic seizure during
labour63.
Perinatal mortality in infants of women with
epilepsy has been found to the two to three times
higher than in the general population in several
retrospective and prospective studies15, 50, 52, 64. A fall
in the perinatal mortality rate was found when the
outcomes of pregnancy were compared from two
periods, 1977 to 1981 and from 1987 to 1991, with
a decrease from 4.7% to 2.1 %, respectively. However,
the mortality rate was alsom consistently two to three
times that of the control group, reflecting improved
perinatal care in more recent years rather than an effect
of changing antiepileptic drug prescriptions64.
Breast feeding and antiepileptic drugs
The drug concentration profile in breast milk follows
the plasma concentration curve, but a delay can often
be seen. The drug concentrations in milk can substan-
tially differ between the first and last portion of the
feed, and between the left and right breast depending
on the fat and protein content65, 66. The total amounts
of drug transferred to the infant via breast milk are
usually much smaller than the amounts transferred
via the placenta during pregnancy. However, as drug
elimination mechanisms are not fully developed in
early infancy, repeated administration of a drug via
breast milk may lead to accumulation in the infant and
pharmacological effects can occur67.
Relatively small amounts of phenytoin are trans-
ferred via breast milk and the serum levels of
phenytoin in breast feeding infants are generally
considerably below therapeutic levels. Phenobarbitone
and primidone can accumulate in plasma in the breast-
fed baby due to slow elimination. It is therefore
recommended that the infant is closely monitored
and serum levels may be indicated. Carbamazapine
concentrations in breast-fed babies are usually low and
below the level where pharmacological effects might
be anticipated. However, very rarely adverse reactions
have occurred. Ethosuximide can be transferred via
breast milk in relatively high daily doses and plasma
concentrations in breast-fed babies can be close to
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therapeutic levels. Sodium valproate levels in breast-
fed babies are low. Vigabatrin and gabapentin are
excreted mainly unchanged in the urine and therefore
in infants with fully developed renal function,
accumulation of these drugs is unlikely66. Lamotrigine
is, to a large extent, glucaronidated and in the newborn
this capacity is not fully developed. A recent study
suggested that lamotrigine can possibly accumulate
in breast-fed infants particularly if a mother is also
taking sodium valproate68. There is no data relating
to topiramate, levatiracetam or tiagabine.
A recent study of child safety in the first year of
life from Birmingham looked at untoward incidents.
All apart from one women who had her first seizure
whilst carrying her child, were potentially preventable.
Mothers with juvenile myoclonic epilepsy seem
particularly at risk as lack of sleep may precipitate
myoclonic jerks and seizures69.
CONCLUSIONS
Therefore, at present the advice to obstetric and
medical teams looking after pregnant women with
epilepsy is to use the lowest possible dose of a suitable
single anticonvulsant which controls seizures, avoid-
ing sodium valproate if possible41a, 48a. The foetus
should be screened by ultrasound for spina bifida,
congenital heart disease and other malformations. In
those women who did not receive advice before their
pregnancy, the opportunity should be taken to refer
them for re-evaluation of their diagnosis and treatment
before further pregnancies occur.
Guidelines for the management of women with
epilepsy have been recently published and should be
incorporated into obstetric unit protocols18, 70.
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